A British Indian doctor is conducting a “blockbuster” cancer vaccine trial.

A British Indian doctor is conducting a “blockbuster” cancer vaccine trial.

A British Indian doctor is conducting a cancer vaccine trial


A British Indian doctor is the principal investigator in a “groundbreaking” trial of a vaccine to treat early bowel cancer in patients around the world, following a UK and Australian collaboration between scientists and doctors.

Dr Tony Dillon, a consultant medical oncologist at the Royal Surrey NHS Foundation Trust, proposed the idea for the trial and has worked with Professor Tim Price in Australia over the past four years to develop the vaccine.

The trial, which was recently announced, will be managed by the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton in collaboration with the Royal Surrey and Queen Elizabeth Hospital in Adelaide, Australia.

“This is the first therapeutic vaccine for any gastrointestinal cancer and we have high hopes that it will be very successful. We believe that for many patients, the cancer will go away completely after this treatment,” Dr. Dillon said.

“This is groundbreaking. I feel as though we’re on the verge of something really big here. The vaccine makes the immune system go after the cancer. This is going to be life-changing because it means patients potentially won’t need to have surgery — they might just get the vaccine,” he said.

There will be 10 patient enrollment sites – six in Australia and four in the UK, with 44 patients enrolled in the study over 18 months.

The vaccine will be used to treat patients before surgery, in the hope that it will cause the body to attack the cancer. This means that any surgery will be less invasive. It is also hoped that the power of the vaccine will support the immune system to respond in the event of a relapse and the cancer subsequently returns.

“We are very proud to be involved in the launch of this pioneering new vaccine. As the UK’s fourth largest cancer centre, helping to fight cancer is a huge part of what we do, and this will really provide an opportunity for bowel cancer patients and give them real hope,” said Louise Stead, Royal. In overcoming disease, CEO of the Surrey Trust.

Patients will have an endoscopy, and then a tissue sample will be tested to see if they qualify for the trial. If they are, they will get three doses of the vaccine before having surgery to remove the cancer.

The trial will be available to only 44 patients worldwide. After the trial ends, the vaccine will be licensed for use or, if successful, a larger study will be conducted.

Bowel cancer, also known as colorectal cancer, is the third most common type of cancer, with an annual incidence worldwide of more than 1.2 million cases and a mortality rate of about 50 percent.

The vaccine was designed by Imugene Ltd, a clinical-stage immuno-oncology company.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

(Marks for translation) British Indian doctor (R) experimenting with a cancer vaccine

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *